TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT05436418: The Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis After Reduced In

Sponsor: National Cancer Institute (NCI) · Phase: PHASE1/PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 260 pts

Competing Trials Overlap

4 Active Trials

Excess Burn Exposure

$9,030,400

Rescue Site Savings

+$5,954,420

Unlock Full NCT05436418 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT05436418 Rescue Dossier →